1. Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer. In Vivo. 2022 Jul-Aug;36(4):1903-1910.
2. Survival Outcomes With Reduced Doses of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.In Vivo. 2022 Jul-Aug;36(4):1868-1874.
3. Survival Impact of Residual Cancer Cells in Intraoperative Peritoneal Washes following Radical Hysterectomy for Cervical Cancer. J Clin Med. 2022 May 9;11(9):2659.
4. Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer.Anticancer Res. 2022 Jan;42(1):349-353.
5. Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer. Anticancer Res. 2021 Dec;41(12):6287-6292.
6. Prognostic Value of Lymph Node Characteristics in Patients with Cervical Cancer Treated with Radical Hysterectomy. Cancer Manag Res. 2021 Oct 28;13:8137-8145.
7. Predicting Tumor Budding Status in Cervical Cancer Using MRI Radiomics: Linking Imaging Biomarkers to Histologic Characteristics. Cancers (Basel. 2021 Oct 14;13(20):5140.
8. Prediction Model for Tumor Budding Status Using the Radiomic Features of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Cervical Cancer. Diagnostics (Basel). 2021 Aug 23;11(8):1517.
9. Intratumoral budding: A novel prognostic biomarker for tumor recurrence and a potential predictor of nodal metastasis in uterine cervical cancer. Eur J Surg Oncol. 2021 Dec;47(12):3182-3187.
10. A uterine cervix supporting device (Con-CapTM) for reducing canal stenosis after Loop Electrosurgical Excisional Procedure.Technol Health Care. 2021;29(5):955-962. 등